Quantitative Determination of Fluoxetine in Pharmaceuticals and Plasma Samples Using Bromatometric Method


Asensitive and simple spectrophotometric method has been developed for quantitative determination of fluoxetine using bromatometric method. The method is based on the addition of measured excess amount of bromate-bromide mixture to fluoxetine in hydrochloric acid medium. The residual bromine was determined by reacting with a fixed amount ofmethyl orange and absorbance was measured at 505 nm. The amount of bromine reacted corresponds to the amount of fluoxetine. Linear relationship between absorbance and fluoxetine concentration was found and Beer’s law was obeyed in the concentration range of 0.4 - 12 μg·mL–1. The molar absorptivity was found to be 3.8 × 104 L·mol–1·cm–1. The limit of detection and limit of quantification was calculated and found to be 0.32 μg·mL–1 and 1.0 μg·mL–1respectively. The common excipients were investigated for their interferences effect in the assay. The validity of the developed method was checked through recoveries studies and successfully applied to the determination of fluoxetine in bulk powder, pharmaceutical formulations and spiked human plasma samples. The percent recoveries were found to be in the range of 97.0% - 101.0% for pharmaceutical formulations and from 97.0% - 99.0% for spiked human plasma.

Share and Cite:

J. Shah, M. Jan, M. Khan and S. Durrani, "Quantitative Determination of Fluoxetine in Pharmaceuticals and Plasma Samples Using Bromatometric Method," American Journal of Analytical Chemistry, Vol. 3 No. 12, 2012, pp. 828-835. doi: 10.4236/ajac.2012.312109.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. Parfitt, “Martindale: The Complete Drug Reference,” 33rd Edition, Pharmaceutical Press, London, 2002.
[2] J. E. F. Reynolds, “Martindale: The Extra Pharmacopeia,” 31st Edition, Royal Pharmaceutical Society, London, 1996, p. 312.
[3] J. F. Wernicke, “The Side Effect Profile and Safety of Fluoxetine,” Journal of Clinical Psychology, Vol. 46, No. 3, 1985, pp. 59-67.
[4] T. A. Piggott and S. M. Seay, “A Review of the Efficacy of Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder,” Journal of Clinical Psychology, Vol. 60, No. 2, 1999, pp.101-106.
[5] F. Gevirtz, K. Way, C. H. Young, T. Coleman and K. Gregor, “SSRI-to-SSRI Switching and Associated Dosing Characteristics,” Journal of Managed Care Pharmacy, Vol. 5, No. 2, 1999, pp. 138-143.
[6] F. Bueno, A. M. Bergold and P. E. Froehlich, “Assay of Fluoxetine Hydrochloride by Titrimetricand HPLC Methods,” Bollettino Chimico Farmaceutico, Vol. 139, No. 6, 2000, pp. 256-259.
[7] M. Shamsipur, L. S. Dastjerdi, S. Haghgoo, D. Armspach, D. Matt and H. Y. Aboul-Enein, “Chiral Selectors for Enantioresolution and Quantitation of the Antidepressant Drug Fluoxetine in Pharmaceutical Formulations by 19F NMR Spectroscopic Method,” Analytica Chimica Acta, Vol. 601, No. 1, 2007, pp.130-138. doi:10.1016/j.aca.2007.08.017
[8] J. Atta-Politou, I. Skopelitis, I. Apatsidis and M. Koupparis, “In Vitro Study on Fluoxetine Adsorption onto Charcoal Using Potentiometry,” European Journal of Pharmaceutical Sciences, Vol. 12, No. 3, 2001, pp. 311- 319. doi:10.1016/S0928-0987(00)00187-1
[9] C. R. Shah, N. J. Shah, B. N. Suhagia and N. M. Patel, “Simultaneous Assay of Olanzapine and Fluoxetine in Tablets by Column High-Performance Liquid Chromatography and High-Performance Thin-Layer Chromatography,” Journal of AOA CInternational, Vol. 90, No. 6, 2007, pp. 1573-1578.
[10] M. T. Maya, C. R. Domingos, M. T. Guerreiro and J. A. Morais, “Determination of the Antidepressant Fluoxetine in Human Plasma by LC with UV Detection,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 23, No. 6, 2000, pp. 989-996. doi:10.1016/S0731-7085(00)00367-8
[11] M. A. Raggi, G. Casamenti, R. Mandrioli, C. Sabbioni and V. Volterra, “A Rapid LC Method for the Identification and Determination of CNS Drugs in Pharmaceutical Formulations,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 23, No. 19, 2000, pp. 161-167. doi:10.1016/S0731-7085(00)00265-X
[12] N. Yilmaz, Y. Ozkan, S. A. Ozan, I. Biryol and H. Y. Aboul-Enein, “High Performance Liquid Chromatographic Assay and Drug Dissolution Studies of Fluoxetine Hydrochloride in Capsule Formulations,” Journal of Liquid Chromatography and Related Technology, Vol. 23, No. 11, 2000, pp. 1699-1710. doi:10.1081/JLC-100100446
[13] A. Lucca, G. Gentilini, S. Lopez-Silva and A. Soldarini, “Simultaneous Determination of Human Plasma Levels of Four Selective Serotonin Reuptake Inhibitors by High-Performance Liquid Chromatography,” Therapeutic Drug Monitoring, Vol. 22, No. 3, 2000, pp. 271-276. doi:10.1097/00007691-200006000-00007
[14] I. Meineke, K. Schreeb, I. Kress and U. Gundert-Remy, “Routine Measurement of Fluoxetine and Norfluoxetine by High-Performance Liquid Chromatography with Ultraviolet Detection in Patients under Concomitant Treatment with Tricyclic Antidepressants.” Therapeutic Drug Monitoring, Vol. 20, No. 1, 1998, pp. 14-19. doi:10.1097/00007691-199802000-00003
[15] E. Lacassie, J. M. Gaulier, P. Marquet, J. F. Rabatel and G. Lachatre, “Methods for the Determination of Seven Selective Serotonin Reuptake Inhibitors and Three ActiveMetabolites in Human Serum Using High-Performance Liquid Chromatography and Gas Chromatography,” Journal of Chromatography B and Biomedical Science application, Vol. 742, No. 2, 2000, pp. 229-238.
[16] J. J. Berzas-Navado, M. J. Villasenor-Lierena, A. M. Contento-Salcedo and E. Aguas-Nuevo, “Determination of Fluoxetine, Fluvoxamine, and Clomipramine in Pharmaceutical Formulations by Capillary Gas Chromatography,” Journal of Chromatographic Science, Vol. 38, No. 5, 2000, pp. 200-206.
[17] N. H. Jourdil, P. D. Fontanille and G. M. Bessard, “Concurrent Determination of Second-Generation Anti-Depressants in Plasma by Using Gas Chromatography with Nitrogen-Phosphorus Detection,” Clinical Chemistry, Vol. 43, No. 11, 1997, pp. 2209-2210.
[18] T. Buzinkaiova and J. Polonsky, “Determination of Four Selective Serotonin Reuptake Inhibitors by Capillary Isotachophoresis,” Electrophoresis, Vol. 21, No. 14, 2000, pp. 2839-2841. doi:10.1002/1522-2683(20000801)21:14<2839::AID-ELPS2839>3.0.CO;2-J
[19] J. J. Berzas-Navado, A. M. Contento-Salcedo, M. J. Villasenor-Llerena and E. Aguas-Nuevo, “Method Development and Validation for the Simultaneous Determination of Fluoxetine and Fluvoxamine in Pharmaceutical Preparations by Capillary Electrophoresis,” Analytica Chimica Acta, Vol. 417, No. 2, 2000, pp. 169-176. doi:10.1016/S0003-2670(00)00926-0
[20] I. A. Darwish, S. M. Amer, H. H. Abdine and L. I. Al-Rayes, “New Spectrophotometric and Fluorimetric Methods for Determination of Fluoxetine in Pharmaceutical Formulations,” International Journal of Analytical Chemistry, Vol. 2009, Article ID 257306, pp. 1-9. doi:10.1155/2009/257306
[21] A. Afkhami, T. Madrakian and L. Khalafi, “Spectrophotometric Determination of Fluoxetine by Batch and Flow Injection Methods,” Chemical and Pharmaceutical Bulletin, Vol. 54, No. 12, 2006, pp. 1642-1644. doi:10.1248/cpb.54.1642
[22] H. P. Anandkumari, B. P. Vandana, and G. Rajani, “Spectrophotometric Determination of Fluoxetine Using Methyl Orange and Thymol Blue to Form Ion Pair Complex,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 20, No. 3, 1999, pp. 427-432.
[23] J. Shah, M. R. Jan and F. Rehman, “Flow Injection Spectrophotometric Determination of Fluoxetine in Bulk and in Pharmaceutical Preparations,” Journal of the Chilean Chemical Society, Vol. 53, No. 3, 2008, pp. 1605-1608. doi:10.4067/S0717-97072008000300011
[24] International Conference on Harmonization, “Validation of Analytical Procedures: Test and Methodology,” Vol. 60, Federal Register, London, 1996, p. 11260.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.